Vivos Therapeutics (VVOS) Current Deferred Revenue (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Current Deferred Revenue data on file, last reported at $495000.0 in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 16.67% year-over-year to $495000.0 in Q1 2026; TTM through Mar 2026 was $495000.0, a 16.67% decrease from a year earlier, with the FY2025 full-year figure at $479000.0, down 51.76% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $495000.0, up from $479000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for VVOS reached as high as $3.0 million in Q4 2022 and fell as low as $479000.0 in Q4 2025.
• Historically, Current Deferred Revenue has averaged $1.8 million across 5 years, with a median of $2.2 million in 2022.
• Across the five-year window, Current Deferred Revenue jumped 34.06% in 2023 and sank 79.73% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $3.0 million in 2022, then fell by 20.11% to $2.4 million in 2023, then tumbled by 59.09% to $993000.0 in 2024, then sank by 51.76% to $479000.0 in 2025, then increased by 3.34% to $495000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $495000.0 in Q1 2026, $479000.0 in Q4 2025, and $537000.0 in Q3 2025.